ASCO 2024 | The current treatment landscape for multiple myeloma and trials investigating novel combinations
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, provides an overview of the treatment panorama for multiple myeloma (MM). He discusses quadruplet therapies combining daratumumab with chemotherapy in frontline settings, stratification of treatment in the relapsed/refractory (R/R) setting based on lenalidomide response, and the high efficacy of belantamab mafodotin with bortezomib and dexamethasone observed in the DREAMM-7 trial (NCT04246047). He also mentions promising novel agents like bispecific antibodies, CAR-Ts, and melflufen in MM treatment. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
